Results of a phase 2b trial with GB001, a DP2 antagonist, in moderate-to-severe eosinophilic asthma. Moss MH, Lugogo NL, Castro M, Hanania NA, et al. Chest 2022 Mar 3. pii: S0012-3692(22)00405-6. doi: 10.1016/j.chest.2022.

Read + Share

Amedeo Smart

Independent Medical Education

Moss MH, Lugogo NL, Castro M, Hanania NA, et al. Results of a phase 2b trial with GB001, a DP2 antagonist, in moderate-to-severe eosinophilic asthma. Chest 2022 Mar 3. pii: S0012-3692(22)00405-6. doi: 10.1016/j.chest.2022.
PMID: 35248549